Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Juvena Therapeutics develops tissue-restorative biologics to address chronic muscle and age-related conditions.
Recludix pharma is a developing platform to treat cancer patients.
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
InduPro deevlops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease.
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.
ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology diseases.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.
Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Signify Bio is a biotechnology company harnessing the human body for the production of in situ protein therapeutics.
Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.
Eli Lilly has invested in 169 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Eli Lilly's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 13 different industry categories.
Among tracked funding rounds, Sanegene Bio received $110.0M in a Series B round. Eli Lilly's total known invested capital is $11.1B.
Eli Lilly's average investment size is $69.2M across its portfolio of 169 companies.
Recent Eli Lilly portfolio additions include TRex Bio, XellSmart, Juvena Therapeutics, Recludix Pharma, ProQR Therapeutics. These companies were founded in 2020 or later.